Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: A comparison to glibenclamide

Diabetes Care

Volumn 25, Issue 12, 2002, Pages 2129-2132

  Haupt, Axel ^a   Kausch, Christiana ^a   Dahl, Dominik ^a   Bachmann, Oliver ^a   Stumvoll, Michael ^a   Häring, Hans U ^a   Matthaei, Stephan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; INSULIN; PHOSPHATIDYLINOSITOL KINASE; ANDROSTANE DERIVATIVE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLYCOGEN; SULFONYLUREA DERIVATIVE; WORTMANNIN;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE TOLERANCE; GLYCOGEN SYNTHESIS; HUMAN; HUMAN CELL; MUSCLE CELL; MYOTUBE; SKELETAL MUSCLE; BIOSYNTHESIS; CELL CULTURE; CULTURE TECHNIQUE; FEMALE; GENETICS; KINETICS; MALE; METABOLISM; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANDROSTADIENES; CELL CULTURE TECHNIQUES; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; GLYCOGEN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; MALE; MUSCLE, SKELETAL; SULFONYLUREA COMPOUNDS;

EID: 0038758896     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.12.2129     Document Type: Article

References (35)

1. Simonson DC: Effects of glyburide on in vivo insulin-mediated glucose disposal. Am J Med 89 (Suppl. 2A):44S-50S, 1990
2. Pontiroli AE, Alberetto M, Bertoletti A, Baio G, Pozza G: Sulfonylureas enhance in vivo the effectiveness of insulin in type 1 (insulin dependent) diabetes mellitus. Horm Metabol Res 16:167-170, 1984
3. Pernet A, Trimble ER, Kuntschen F, Assal JP, Hahn C, Renold AE: Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo. J Clin Endocrinol Metab 61:247-251, 1985
4. Keller U, Mūller R, Berger W: Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects. Horm Metabol Res 18:599-603, 1986
5. Leblanc H, Thote A, Chatellier G, Passa P: Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics. Diabete Metab 16:93-97, 1990
6. Schulz B, Ratzmann KP, Heinke P, Besch W: A stimulatory effect of tolbutamide on the insulin-mediated glucose uptake in subjects with impaired glucose tolerance (IGT). Exp Clin Endocnnol 82:222-231, 1983
7. Kolterman OG, Olefsky JM: The impact of sulfonylurea treatment upon the mechanism responsible for the insulin resistance in type II diabetes. Diabetes Care 7 (Suppl. 1):81-88, 1984
8. Greenfield MS, Doberne L, Rosenthal M, Schulz B, Widstrom A, Reaven GM: Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus. Diabetes 31:307-312, 1982
9. Kolterman OG: Longituinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus. Am J Med 79:23-33, 1985
10. Ward G, Harrison LC, Proietto J, Aitken P, Nankervis A: Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects. Diabetes 34:241-245, 1985
11. Langtry HD, Balfour JA: Glimepiride: a review of its use in the management of type 2 diabetes mellitus. Drugs 55:563-584, 1998
12. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V: Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39:1617-1624, 1996
13. Kramer W, Müller G, Geisen K: Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at β-cells. Horm Metal Res 28:464-468, 1996
14. Müller G, Geisen K: Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Hom Metab Res 28:469-487, 1996
15. Ashcroft FM: Mechanism of the glycaemic effects of sulfonylureas. Horm Metab Res 28:456-463, 1996
16. Mūller G, Satoh Y, Geisen K: Extrapancreatic effects of sulfonylureas: a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 28 (Suppl. 28):S115-S137, 1995
17. Clark HE, Matthews DR: The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 28:445-450, 1996
18. Rosenstock J, Samols E, Muchmore DB, Schneider J: Glimepiride, a new once-daily sulfonylurea. Diabetes Care 19:1194-1199, 1996
19. Dills DG, Schneider J: Clinical Evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 28:426-429, 1996
20. Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E, Robkamp R: Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 28:419-425, 1996
21. Riddle MC: Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. Horm Metab Res 28:430-433, 1996
22. Goldberg RB, Holvey SM, Schneider J: A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents: the Glimepiride Protocol #201 Study Group. Diabetes Care 19:849-856, 1996
23. Robkamp R, Wernicke-Panten K, Draeger E: Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract 31 (Suppl. 31):S33-S42, 1996
24. Campbell RK: Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 32:1044-1052, 1998
25. Massi-Benedetti M, Herz M, Pfeiffer C: The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm Metab Res 28:451-455, 1996
26. Krützfeld J, Kausch C, Volk A, Klein HH, Rett K, Häring HU, Stumvoll M: Insulin signaling and action in cultured skeletal muscle cells from lean healthy humans with high and low insulin sensitivity. Diabetes 49:992-998, 2000
27. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP: Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects: comparison using human skeletal muscle cell cultures. Diabetes 44:936-946, 1995
28. Marynissen G, Smets G, Klöppel G: Internalisation of glimepiride and glibenclamid in the pancreatic B-cell. Acta Diabetol 29:113-114, 1992
29. Kawamori R, Morihima T, Kubota M, Ineda K, Kamada T: Influence of oral sulfonyklurea agents on hepatic glucose uptake. Diabetes Res Clin Pract 28 (Suppl.1):109-113, 1995
30. Müller G: The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol Med 6:907-933, 2000
31. Müller G, Wied S: The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin resistent rat adipocytes in vitro. Diabetes 42:1852-1876, 1993
32. Müller G, Geisen K: Characterisation of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Horm Metab Res 28:469-487, 1996
33. Takada Y, Takata Y, Iwanishi M, Imamura T, Sawa T, Morioka H, Ishihara H, Ishiki M, Usui I, Temaru R, Urakaze M, Satoh Y, Inami T, Tsuda S, Kobayashi M: Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscle from genetically diabetic KK-Ay mouse. Eur J Pharmacol 308:205-210, 1996
34. Reimann F, Gribble FM, Ashcroft FM: Differential response of K(ATP) channels containing SUR2A or SURB subunits to nucleotides and pinacidil. Mol Pharmacol 58:1318-1325, 2000
35. Olbrich HG, Mueller M, Lindner S, Henke B, Zarse M, Riehle M, Oremek G, Mutschler E: Glimpepiride inhibits the rilmakalim induced decrease in intracellular free calcium and contraction of isolated heart muscle cells from guinea pigs to a lesser extent than glibenclamide. Int J Cardiol 72:53-63, 1999